- Home
- SQFT vs ENVB Comparison
SQFT vs ENVB Comparison
Compare SQFT & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | ENVB |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | SQFT | ENVB |
|---|---|---|
| Price | $3.12 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 14.2K | ★ 262.0K |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $23.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.52 | $0.56 |
| 52 Week High | $23.00 | $13.25 |
Technical Indicators
Market Signals| Indicator | SQFT | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 32.01 |
| Support Level | $2.60 | $1.96 |
| Resistance Level | $3.08 | $4.29 |
| Average True Range (ATR) | 0.22 | 0.20 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 74.74 | 10.26 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.